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Abstract-We have examined the effect of the oral gold compound auranofin (AF) on calcium ionophore 
A23187-induced arachidonic acid metabolism in the rat alveolar macrophage. Both reverse-phase high 
performance liquid chromatographic and radioimmunoassay analyses revealed that AF dose-dependently 
inhibited leukotriene B4 and 5-hydroxyeicosatetraenoic acid synthesis in a parallel fashion with an 
%I - 4.3 pg/ml. At the same time, AF augmented A23187-induced arachidonate release and cyclooxy- 
genase metabolism. A possible mechanism for the inhibition of 5-lipoxygenase was suggested by the 
capacity of AF to dose-dependently deplete ATP (ICY - 5.9 pg/ml), a cofactor for 5-iipoxygenase. 
These data indicate that, at therapeutic concentrations, AF acts in vitro as a selective in~bitor of 
macrophage 5-lipoxygenase metabolism. This likely represents an implant mechanism of action of 
AF in chronic inflammatory disorders. 
Chrysotherapy has well-established efficacy in the 
treatment of rheumatoid arthritis [l]. In addition, 
gold salts have been shown to attenuate airway 
responsiveness in animals [2] as well as humans [3], 
and to decrease symptom scores and medication 
requirements in patients with asthma [3,4]. It is 
generally recognized that chronic inflammation plays 
a prominent role in the pathogenesis of both rheu- 
matoid arthritis [S] and asthma [6], and prominent 
among the many potential mediators of inflammation 
which have been suggested to be impo~ant in these 
conditions are the eicosanoids, a group of oxy- 
genated derivatives of arachidonic acid (AA) [7]. 
Recent studies have demonstrated that auranofin 
(AF), an oral gold compound, inhibits the synthesis 
of leukotrienes, potent pro-inflammatory 5-lipoxy- 
genase metabolites of AA, in human blood neu- 
trophils [8,9], basophils [lo], and lung mast cells 
WI* 
Although the macrophage is thought to play a 
central role in chronic inflammatory disorders [ll], 
has the capacity to release relatively large amounts 
of cyclooxygenase and 5lipoxygenase eicosanoids 
1121, and is a putative target cell for the anti-inflam- 
matory effects of gold 1131, we are aware of no 
information on the modulation by gold compounds 
of macrophage-derived eicosanoid synthesis. We 
therefore examined the effect of AF on calcium 
ionophore A23187-induced AA metabolism in the 
rat alveolar macrophage (AM), a cell which produces 
large amounts of 5lipoxygenase metabolites includ- 
ing both leukotrienes B4 (LTBI) and C4 (LTC3 
[14]. Our results indicated that AF inhibits AM 5- 
lipoxygenase metabolism at therapeutic concen- 
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trations, and they suggest that the mechanism of 
this inhibitory action may involve the depletion of 
cellular ATP, a cofactor for the 5-lipoxygenase 
enzyme [15,16]. 
METHODS 
Macrophage isolation and culture. Respiratory dis- 
ease-free 125-150 g female Wistar rats were obtained 
from Charles River (Portage, MI) and housed under 
specific pathogen-free conditions. Follo~ng anes- 
thesia with intrape~toneal sodium pentob~bital, 
lungs were surgically excised and Iavaged as pre- 
viously described [17]. Lavage fluid, as well as 
Hanks’ balanced salt solution (HBSS) (GIBCO, 
Grand Island, NY) and medium 199 with modified 
Earle’s salts (M199) (GIBCO) all contained 
100 units/ml penicillin, 100 pg/ml streptomycin, and 
0.25 mg/ml amphotericin B (Antibiotic-Antimycotic 
Solution, Sigma Chemical Co., St. Louis, MO). Cells 
(2 X 106) suspended in 1.5 ml of Ml99 were plated 
in 35 x 10 mm plastic culture dishes (Falcon Plastics, 
Oxnard, CA) and cultured at 37” in a humidified 
atmosphere of 5% COZ in air. After 1 hr, non-adher- 
ent cells were removed by washing twice with HBSS. 
The resultant adherent cell population has been 
found to contain 95% AM by morphologic criteria 
and esterase staining [17] with viability exceeding 
90% as assessed by trypan blue exclusion. Macro- 
phage monolayers were then cultured overnight 
(16 hr) in Ml99 containing 10% heat-inactivated 
newborn calf serum (NCS) (GIBCO) in the presence 
or absence of radiolabeled AA prior to experimental 
incubations. Following overnight culture, these 
monolayers have been found to contain approxi- 
mately 8.5 pg DNA [17] and 100 pg protein 1141. 
Prelabel~ng of macrophage cultures. In selected 
expe~ents, cellular lipids were prelabeled by 
including 0.2 @Zi of ]1-*4C]AA (sp. act. 54-57 mCi/ 
mmol, Dupont-New England Nuclear, Boston, MA) 
in the medium during overnight culture. To remove 
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unincor~rated label, cells were washed with HBSS, 
incubated for an additional hour with Ml99 con- 
taining 10% NCS, and washed again prior to exper- 
imental incubations. The uptake of radiolabel by 
macrophage cultures, determined as described pre- 
viously [17], was routinely 3540%. 
Incubations with A23187 and AF. Auranofin, pro- 
vided by Smith Kline & French Laboratories (Phi- 
ladelphia, PA), was prepared as a stock solution at 
20mg/ml in DMSO, and diluted in Ml99 to final 
desired concentrations. Following overnight incu- 
bation, duplicate cultures of labeled or uniabeled 
AM were washed twice with HBSS and preincubated 
for 15 min with 1 ml of Ml99 alone or Ml99 con- 
taining AF at concentrations ranging from 0.5 to 
l~~g/~. Then calcium ionophore A23187 (Cal- 
biochem-Behring Corp., LaJolla, CA), 10 FM, was 
added and the incubation continued for an additional 
30 min. The final concentration of DMSO in all 
cultures was OS%, which did not affect cell viability 
or eicosanoid synthesis. 
Eicosanoid extractions. Eicosanoids were 
extracted from culture medium using Sep-pak Cls 
cartridges (Waters Associates, Milford, MA) accord- 
ing to the method of Westcott et al. [18]. Methanol/ 
water (80: 20, v/v) eluates containing eicosanoids 
were dried under nitrogen and stored at -70”. 
Recoveries for this extraction procedure, assessed 
using tritiated standards (DuPont-New England 
Nuclear) added to M199, were 65-70% for LTB4, 
LTC4, and thromboxane Bz (TxBz, the stable break- 
down product of TxA2) 1191. 
Radioimmunoassays. LTB4, LTC4, and TxBz in 
medium from unlabeled AM cultures were quanti- 
tated by radioimmunoassays (RIA) performed by 
the Ligand Core Laboratory of the University of 
Michigan Diabetes Research and Training Center. 
Dried lipid extracts were dissolved in 1 ml of phos- 
phate-buffered saline containing 0.1% gelatin 
(pH 7.4), and lOO-~1 aliquots were assayed in dupli- 
cate for each sample. The antibody sources and 
cross-reactivities, and the assay sensitivities for these 
RIA have been described previously [ 141. The speci- 
ficities of the RIA have been confirmed by analyses 
utilizing reverse-phase high performance liquid 
chromatography (RP-HPLC) 120,211. In all cases, 
quantities of immunoreactive eicosanoids reported 
were corrected for recovery. 
Eicosanoid separation by reverse-phase high per- 
formance liquid chromatography. For separation of 
[14C]AA metabolites produced by prelabeled AM, 
lipid extracts of pooled medium from duplicate cul- 
tures were dissolved in 500 ~1 of acetonitrile/water/ 
trifluoroacetic acid (33:67: 0.1, by vol.) and sub- 
jected to RP-HPLC using a Waters HPLC system 
equipped with a Waters 5 pm Bondapak C1s column 
(30 x 0.4 cm) eluted with acetonitrile/water/ 
trifluoroacetic acid at 1 ml/min, as previously 
described [20]. Using this system, cyclooxygenase 
metabolites are eluted during an initial isocratic 
phase (33 : 67 : 0.1, by vol.), followed by lipoxygenase 
metabolites and free AA, which elute during a step- 
wise gradient increase of acetonitrile to 100 : 0 : 0.1 
(by vol.). The eluate was monitored continuously for 
UV absorbance 1210 nm for cyclooxygenase products 
and free AA, 280 nm for LTs, and 235 nm for mono- 
hydroxyeicosatetraenoic acids (HETEs)]. Authentic 
TxB2, prostaglandin (PG) Dz, PGE?, PGF2,, and 6- 
keto-PGF1, were gifts of Dr. J. Pike (Upjohn Co., 
Kalamazoo, MI), and lipoxygenase standards LTB,, 
LTC4, 5-HETE, lZHETE, and 15HETE of Dr. 
J. Rokach (Merck Frosst, Inc., Quebec, Canada). 
Authentic 12-hydroxy-5.8.10-heptadecatrienoic acid 
(HHT) was obtained from the Cayman Chemical 
Co. (Ann Arbor, MI), and arachidonic acid from 
Nu-Chek Prep, Inc. (Elysian, MN). Eluate fractions 
of 1 ml were collected, and radioactivity was quanti- 
tated in 6 ml of ACS scintillant (Amersham, Arling- 
ton Heights, IL) using a Beckman LSl801 
scintillation counter (Beckman Instruments, Inc., 
Fullerton, CA) with a counting efficiency for “C of 
approximately 75%. Radiolabeled eicosanoids were 
identified by their co-elution with authentic 
standards. 
Adenosine triphosphate assay. Cellular ATP was 
determined by the luciferase-luciferin assay [22], as 
previously described [ 191. Briefly, after experimental 
incubation, culture medium was removed and mono- 
layers were scraped with a rubber policeman into 
iced 10mM potassium phosphate, 4 mM MgSOJ 
buffer, pH 7.4. Cell suspensions were placed in a 90- 
95” water bath for 4 min, and then on ice until assay, 
within 4 hr. At the time of assay, an aliquot of cell 
suspension was added to 50 mM NazHAs04, 20 mM 
MgS04 buffer, pH7.4, in a glass scintillation vial. 
Fifty microliters of luciferase-luciferin (Sigma), 
reconstituted in sterile glycine buffer. was added to 
the assay mixture, and light emission was quantitated 
immediately in a Beckman LS1801 counter using the 
single photon monitor mode. Standard curves of log 
cpm versus log [ATP] were linear over the range 
1O-9 to lO+‘M ATP. 
Glutathione assay. Monolayers were deprotein- 
ated with 0.7 M perchloric acid, neutralized with 
2 iM potassium hydroxide, and intracellular total 
(reduced plus oxidized) glutathione was quantitated 
by the glutathione reductase assay [‘23], recording 
the change in absorbance at 412 nm over time with 
a Beckman model 35 spe~trophotometer. The details 
of the cellular processing and of the assay itself were 
as previously described 1141. 
Data analysis. AH data are expressed as 
means rt SE. In all cases, immunoreactive eico- 
sanoid levels in medium and cellular ATP and 
glutathione contents were determined in duplicate 
culture plates for each experimental condition and 
the average calculated to yield a single data point. 
The effect of AF on A23187-stimulated eicosanoid 
synthesis is expressed as the percent of the eicosanoid 
level found in cultures stimulated with A23187 alone, 
after correction for control levels of production. 
Similarly, the effects of AF on cellular content of 
ATP and glutathione are expressed as the percent of 
the content of cells incubated with A23187 alone. 
RESULTS 
A23187-induced AA metabolism. Figure 1A 
depicts a representative [‘4C]eicosanoid RP-HPLC 
elution profile from AM cultures incubated for 
30 min with 10 PM A23187 alone. The major peaks 
of radioactivity co-eluted with authentic standards 
Auranofin inhibition of macrophage 5Jipoxygenase metabolism 1591 
C. An167+AF(3.0~ 
B. A23187 + AF (1.5 P~J'WW 
o lo 20 30 40 50 60 70 60 60 100 110 
Table 1. Immunoreactive eicosanoid synthesis by unstimu- 
lated and A23187-stimulated alveolar macrophages in the 
absence of AF 
Eicosanoid (ng/plate) 
LTC4 LTB4 TxB2 
Control 0.29 * 0.01 0.10 ? 0.02 0.52 rf: 0.09 
A23187 11.30 f 4.33 41.90 2 1.02 1.95 2 0.03 
Thlm mw Tmr ww 
Fig. 1. RF’-HPLC analysis of radiolabeled eicosanoids in culture medium from [ “‘C]AA-prelabeled AM. 
Macrophages were incubated for 30 min with 10 PM A23187 alone (A), or A23187 in the presence of 
AF at 1.5 pg/ml (B), 3 pgg/ml (C), or 10 pg/ml (D). Retention times of authentic standards are indicated 
by arrows. 
Alveolar macrophages (2 x 106) were incubated for 
30 min in the presence or absence of 10 PM A23187, and 
eicosanoids were quantitated in medium by RIA. Each 
value is the mean 2 SE of three individual experiments, 
each performed in duplicate. 
for LTB4, S-HETE, and free AA. Additional smaller 
peaks co-eluted with the lipoxygenase products LTCl 
and lZHETE, as well as the cyclooxygenase metab- 
olites TxB2, PGE2, PGD2, and HI-IT. The eico- 
sanoids LTC4, LTB4, and TxB2 were quantitated 
in unstimulated and A23187-stimulated cultures by 
RIA. and the mean values (N = 3) are summarized 
in Table 1. 
Effects of AF on A23187-induced AA metabolism. 
The effects of 1.5, 3, and lOpg/mi AF on A23187- 
induced macrophage AA metabolism are shown in 
the radioactivity RP-HPLC elution profiles depicted 
in Fig. 1, panels B, C, and D respectively. Ionophore- 
induced LTC4 synthesis was eliminated at 1.5 pg/ 
ml AF, while A23187-induced LTB4 and 5-HETE 
synthesis were inhibited in parallel fashion by AF 
over the concentration range 1.5 to lOpg/ml. In 
contrast, at all doses tested, AF augmented A23187- 
induced release of free AA as well as the cyclooxy- 
genase products TxBz and HHT. That this increase 
in radioactivity in AA, TxB*, and HHT represents 
augmented phospholipase activity and not merely 
a shunting of [14C]arachidonate away from the 5- 
lipoxygenase pathway is suggested by the greater 
total release of radiolabeled AA plus metabolites in 
cultures containing AF. 
To assess in a more quantitative fashion the effects 
of AF on AM arachidonate metabolism, unlabeled 
cultures were incubated with lO@l A23187 in the 
presence and absence of various concentrations of 
AF and eicosanoids measured by RIA. As shown in 
Fig. 2, AF dose-dependently inhibited LTC4 
(IC,, - 1 &ml, ~90% inhibition at 5 pg/ml) with 
greater potency than LTB, (1~~~ - 4.3 fig/ml, >90% 
inhibition at 10 pg/ml). AF dose-dependently aug- 
mented A23187-induced TxB2 synthesis by as much 
as 5-fold over the same concentration range at which 
it inhibited LT synthesis (Fig. 2). Thus, both RP- 























Fig. 2. Effect of AF concentration on A23187-induced 
synthesis of immunoreactive eicosanoids. Alveolar macro- 
phages were incubated for 30 min with 10 PM A23187 either 
alone or in the presence of various concentrations of AF. 
Immunoreactive LTB4, LTCJ, and TxB, were quantitated 
in culture medium, and the data are expressed as the 
percent of the quantities produced by A23187-stimulated 
cultures alone. Each point represents the mean +- SE from 
duplicate determinations in three independent 
experiments. 
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Fig. 3. Effect of AF concentration on ATP content in AM 
incubated with A23187. Cultures were incubated for 30 min 
with 10,nM A23187 alone or in the presence of AF at 
the indicated concentrations. Cellular ATP content was 
determined by the luciferase-luciferin method, and the 
results are expressed as the percent of the ATP content of 
cultures incubated with A23187 alone. Data represent the 
mean values 2 SE from duplicate determinations in three 
independent experiments. 
HPLC and RIA experiments demonstrated that AF: 
(1) inhibited LT synthesis while augmenting AA 
release and cyclooxygenase metabolism; and (2) 
inhibited the synthesis of LTC, with greater potency 
than other 5-lipoxygenase eicosanoids. 
Effects of AF on macrophage A TP content. Using 
the luciferase/luciferin method, we determined the 
ATP content of cells following 30 min of incubation 
with lO@M A23187 in the presence and absence of 
various concentrations of AF. The effects of AF on 
cellular ATP levels were determined relative to the 
ATP content of AM cultures containing A23187 
alone both to duplicate the conditions under which 
eicosanoid levels were evaluated and because we 
have observed previously an independent ATP- 
depleting effect for A23187 1191. In the current study, 
the ATP content of AM cultures incubated with 
A23187 alone in the absence of AF was 
269 +- 77 pmoI/plate (N = 3). As shown in Fig. 3, 
0 




Fig. 4. Effect of AF concentration on intracellular 
glutathione content in AM incubated with A23187. Cul- 
tures were incubated for 30 min with 10 PM A23187 alone 
or in the presence of AF at the indicated concentrations. 
Total glutathione content was determined by the glutathi- 
one reductase method, and results are expressed as the 
percent of the value determined for cultures incubated 
with A23187 alone. Data represent the mean values i SE 
from duplicate determinations in three independent 
experiments. 
AF effected a dose-dependent depletion of cellular 
ATP, with an 1c5c - 5.9 pg/ml. To evaluate the 
potential for AF to interfere with the luciferase/ 
luciferin assay itself, different concentrations of AF 
were added directly to the assay buffer and ATP 
standard curves were generated. At final AF 
concentrations G 10 pg/ml the gold compound had 
no effects on the ATP assay. Substantial interference 
with the measurement of ATP was observed at final 
AF ~ncentrations > 10 pg,/ml, however (data not 
shown). 
Effects of AF on macruphage gIutath~one content. 
To examine the possibility that the preferential inhi- 
bition by AF of LTCl synthesis, as compared to 
LTB4 synthesis, was related to its ability to conjugate 
reduced glutathione, thereby decreasing the amount 
available for LTC4 synthesis [24], we measured total 
glutathione levels in AM cultures. The glutathione 
content following 30 min of incubation with A23187 
in the absence of AF was 369 ? 80 pmol/plate (N = 
3). Auranofin exposure depleted cellular glutathione 
in a dose-dependent fashion, albeit with a potency 
far less than that observed for the inhibition of LTC, 
synthesis by AF; the Q for glutathione was - 8 Fg/ 
ml, and 90% depletion was achieved at an AF con- 
centration between 50 and lOOpg/ml (N = 3) (Fig. 
4). 
DISCUSSION 
Although other investigators have examined the 
effects of AF on LT synthesis in several different cell 
types [8-lo], no information is available regarding its 
effects on the synthesis of LT and other oxygenated 
metabolites of AA by macrophages. Yet this issue 
is particularly germane to understanding the anti- 
inflammatory actions of AF, for the following 
reasons: (1) macrophages are thought to play a key 
role in the pathogenesis of chronic inffammatory 
disorders such as rheumatoid arthritis and asthma 
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[ll]; (2) the macrophage is generally regarded as an 
important target cell for the effects of chrysotherapy 
[ 131; and (3) as compared to most other inflammatory 
cells, including the neutrophil, the macrophage has 
the capacity to synthesize larger quantities [25] as 
well as a more diverse spectrum of eicosanoids, 
including both LX, and LTB., as well as a variety 
of cyclooxygenase metabolites [12]. We therefore 
undertook the present study to examine com- 
prehensively the modulatory effects of AF on AA 
metabolism by the rat AM, a cell whose profile of 
eicosanoid synthesis appears to closely resemble that 
of the human AM [26]. Ionophore A23187 was selec- 
ted as an agonist because it is a potent stimulus for 
arachidonate metabolism via both cyclooxygenase 
and lipoxygenase pathways which bypasses the need 
for specific receptor interactions; as such, it can be 
regarded as a maximal stimulus of AA metabolism 
1271. 
Analysis by RP-HPLC of the eicosanoid products 
of prelabeled AM indicated that A23187 stimulated 
the release of free AA and its metabolism to 
S-lipoxygenase products (LTB, > 5-HETE > 
LTC.+) to a greater extent than cyclooxygenase pro- 
ducts (HHT = TxB2 = PGDz > PGEz). Auranofin 
caused a parallel inhibition of both LTB4 and 5- 
HETE synthesis by AM. This suggests that its inhibi- 
tory site of action was the 5lipoxygenase enzyme 
itself, consistent with the findings of Honda and co- 
workers for intact neutrophils as well as cell-free 
homogenates [9]. Also in agreement with other 
reports [8,9], AF inhibited A23187-induced LTCl 
synthesis (IC& - 1 fig/ml) with greater potency than 
that observed for LTB4 synthesis (K& - 4.3 pg/ml), 
as revealed by both RP-HPLC and RIA analyses. 
The concentrations of AF at which we observed 
inhibition of LT synthesis are within the ranges 
reported by other investigators in blood neutrophils 
[8,9] as well as basophils and lung mast cells [lo]. 
In addition, as therapeutic AF concentrations in 
blood are in the 2-3 pug/ml range [28], and as gold 
has been shown to concentrate in macrophages at 
inflammatory sites [29], including alveolar macro- 
phages 1301, it is likely that the AF concentrations 
required for inhibition of LTC4, as well as LTB4, 
synthesis in the present study can be achieved locally 
at sites of inflammation in vivo. 
It is important to note that the inhibitory effects of 
AF in our system were specific for the 5lipoxygenase 
pathway; the cyclooxygenase pathway, as assessed 
by both RIA and RP-HPLC quantitation of TxB2, 
the major cyclooxygenase metabolite of the rat AM 
[14], was spared. Such specificity is consistent with 
the findings of Parente et al. [8] that AF inhibits 
neutrophil synthesis of LT, but not PGEr. In fact, 
our data indicated that A23187-induced TxBr syn- 
thesis was augmented over the same concentration 
range at which LT synthesis was inhibited. Analysis 
by RP-HPLC of the total products of prelabeled cells 
suggests that this refIects an actual au~entation of 
total phospholipase activity by AF, rather than mere 
shunting away from the 5lipoxygenase pathway. In 
this regard, it is relevant that AF has been shown 
recently to stimulate phospholipase C activity in 
sonicates of a murine macrophage-like cell line [31]. 
ATP is a cofactor for 5-lipoxygenase [U, 161, and 
we have reported recently that ATP depletion 
accounts for the inhibition of AM 5-lipoxygenase 
caused by both unsaturated fatty acids [19] and 
hydrogen peroxide 1321. Because AF is thought to 
interfere with ~tochond~al unctions 1331, we con- 
sidered the possibility that an ATP-depleting effect 
may similarly play a role in its inhibition of 5-lipoxy- 
genase. Our data suggest such a possibility, as the 
IC~~ for ATP depletion was similar to that for LTBq 
synthesis inhibition. A definitive causal link between 
the capacities of AF to inhibit Nipoxygenase and 
deplete cellular ATP remains to be established, 
however. We speculate that ATP depletion may also 
play a role in the cytotoxicity and alterations in 
plasma membrane morphology attributed to AF [33]. 
We next considered the possibility that the pref- 
erential inhibition by AF of macrophage LTC,+, as 
opposed to LTB4 and 5-HETE synthesis, may be 
related to the capacity to conjugate reduced 
glutathione based on its sulfhydryl reactivity [33]. 
We have demonstrated previously [14] that the 
sulfhydryl reactant N-ethylmaleimide depletes AM 
glutathione with the consequence that synthesis of 
LTC,, which is formed by the glutathione transfer- 
ase-catalyzed conjugation of reduced glutathione 
and LTA,, is specifically inhibited. Our results 
demonstrated that AF did indeed deplete cellular 
glutathione, but the dose-response relationships for 
glutathione depletion and LTCl inhibition suggest 
that these two phenomena were not causally related. 
A likely alternative explanation for the preferential 
in~bition of LTC4 synthesis is the higher Km value 
for LTA4 of glutathione transferase (catalyzing LTC4 
synthesis) than of LTAl hydrolase (catalyzing LTB4 
synthesis) [9]. The consequence of such a difference 
in K,,, values would be that, as LTA4 levels decline 
due to S-lipoxygenase inhibition, LTC4 synthesis 
would be more susceptible to substrate limitation 
than would LTB4 synthesis. In accord with this possi- 
bility, we have observed a similar preferential inhi- 
bition of LTC., versus LTBd synthesis in the settings 
of 5-lipoxygenase inhibition caused by both unsatu- 
rated fatty acids [19] and hydrogen peroxide [32]. 
Leukotriene C4 increases microvascular 
permeability, while LTB4 is a leukocyte chemo- 
attractant which also stimulates leukocyte adherence 
and activation as well as modulating lymphocyte 
proliferation, differentiation, and function [7]. In 
addition, of particular relevance to the pathogenesis 
of asthma are the capacities of LTB, to increase 
airway reactivity 1341 and of LTC, to cause bron- 
choconstriction [35] and stimulate mucus secretion in 
airways 1361. Our results indicate that, at therapeutic 
concentrations, AF, an oral gold compound 
approved for use in the United States, acts in vitro 
as a selective inhibitor of macrophage 5-lipoxygenase 
metabolism. For all of these reasons, it is likely that 
inhibition of macrophage LT synthesis represents an 
important mechanism of action of AF in chronic 
in~ammatory disorders such as rheumatoid arthritis 
and asthma. 
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